The effects of histone deacetylase inhibitor and calpain inhibitor combination therapies on ovarian cancer cells

Anticancer Research

Volumn 36, Issue 11, 2016, Pages 5731-5742

  Lapinska, Karolina ^a,b   Housman, Genevieve ^c   Byler, Shannon ^d   Heerboth, Sarah ^e   Willbanks, Amber ^a   Oza, Anuja ^a   Sarkar, Sibaji ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Quinnipiac University   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Autophagy; Calpain; Cell cycle; Combination therapy; Epigenetic drugs; Histone deacetylase inhibitors; Methylation; Ovarian cancer

Indexed keywords

BUTYRIC ACID; CALPEPTIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P21; VORINOSTAT; CALPASTATIN; GLYCOPROTEIN; HISTONE DEACETYLASE INHIBITOR;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER INHIBITION; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DNA METHYLATION; DRUG MECHANISM; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GENE; TUMOR SUPPRESSOR GENE; FEMALE; HUMAN; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; FEMALE; GLYCOPROTEINS; HISTONE DEACETYLASE INHIBITORS; HUMANS; OVARIAN NEOPLASMS;

EID: 84993949901     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: 10.21873/anticanres.11156     Document Type: Article

References (27)

1. U.S. Cancer Statistics Working Group: United States Cancer Statistics: 1999-2012 Incidence and Mortality Web-based Report. Department of Health and Human Services. Centers for Disease Control and Prevention and National Cancer Institute, 2015.
2. Zweemer RP, Verheijen RH, Menko FH, Gille JJ, van Diest PJ, Coebergh JW, Shaw PA, Jacobs IJ and Kenemans P: Differences between hereditary and sporadic ovarian cancer. Eur J Obst Gynecol Reprod Biol 82(2): 151-153, 1999.
3. Mataga MA, Rosenthal S, Heerboth S, Devalapalli A, Kokolus S, Evans LR and Sarkar S: Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitor. Anticancer Res 32(7): 2523-2529, 2012.
4. Longacre M, Snyder NA, Housman G, Leary M, Lapinska K, Heerboth S, Willbanks A and Sarkar S: A comparative analysis of genetic and epigenetic events of breast and ovarian cancer related to tumorigenesis. Int J Mol Sci 17(5): doi: 103390/ijms17050759, 2016.
5. Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S and Longacre M: Cancer development, progression, and therapy: an epigenetic overview. Int J Mol Sci 14(10): 21087-21113, 2013.
6. Rhoda K, Choonara YE, Kumar P, Bijukumar D, du Toit LC and Pillay V: Potential nanotechnologies and molecular targets in the quest for efficient chemotherapy in ovarian cancer. Expert Opin Drug Deliv 12(4): 613-614, 2015.
7. Tomasina J, Lheureux S, Gauduchon P, Rault S and Malzert-Fréon A: Nanocarriers for the targeted treatment of ovarian cancers. Biomaterials 34(4): 1073-1101, 2013.
8. Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N and Sarkar S: Drug resistance in cancer: an overview. Cancers (Basel) 6(3): 1769-1792, 2014.
9. Heerboth S, Lapinska K, Snyder N, Leary M, Rollinson S and Sarkar S: Use of epigenetic drugs in disease: an overview. Genet Epigenet 6(9): 9-19, 2014.
10. Sarkar S, Goldgar S, Byler S, Rosenthal S and Heerboth S: Demethylation and re-expression of epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination therapy. Epigenomics 5(1): 87-94, 2013.
11. Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K and Sarkar S: Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res 34(3): 1071-1077, 2014.
12. Byler S and Sarkar S: Do epigenetic drug treatments hold the key to killing cancer progenitor cells? Epigenomics 6(2): 161-165, 2014.
13. Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, Willbanks A and Sarkar S: EMT and tumor metastasis. Clin Transl Med 4(6): doi: 10.1186/s40169-015-0048-3, 2015.
14. Cacan E, Ali MW, Boyd NH, Hooks SB and Greer SF: Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance. PLoS One 9(1): e87455, 2014.
15. Sarkar S, Abujamra AL, Loew JE, Forman LW, Perrine SP and Faller DV: Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer Res 31(9): 2723-2732, 2011.
16. Frew AJ, Lindemann RK, Martin BP, Clarke CJP, Sharkey J, Anthony DA, Banks K-M, Haynes NM, Gangatirkar, Stanley K, Bolden J, Takeda K, Yagita H, Secrist JP, Smyth MJ and Johnstone RW: Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci USA 105(32): 11317-11322, 2008.
17. Sarkar S and Faller DV: T-oligos inhibit growth and induce apoptosis in human ovarian cancer cells. Oligonucleotides 21(1): 47-53, 2011.
18. Sarkar S and Faller DV: Telomere-homologous G-rich oligonucleotides sensitize human ovarian cancer cells to TRAIL-induced growth inhibition and apoptosis. Nucleic Acid Ther 23(3): 167-174, 2013.
19. Lapinska K, Housman G, Heerboth S, Longacre M and Sarkar S: Anticancer effects of histone deacetylase inhibitors and calpain inhibitor. Int J of Mol Med 32: S16, 2013.
20. Sarkar S: Methods for identifying compounds for treatment of thrombotic condition. Patent No: US 8,586,292B2, 2013.
21. Storr SJ, Carragher NO, Frame MC, Parr T and Martin SG: The calpain system and cancer. Nat Rev Cancer 11(5): 364-374, 2011.
22. Ho W, Pikor L, Gao Y, Elliott BE and Greer PA: Calpain 2 regulates Akt FoxO-p27Kip1 protein signaling pathway in mammary carcinoma. J Biol Chem 287(19): 15458-15365, 2012.
23. Brenet F, Moh M, Funk P, Feierstein E, Viale AJ, Socci ND and Scandura JM: DNA methylation of the first exon is tightly linked to transcriptional silencing. PLoS One 6(1): e14524, 2011.
24. Wang Y and Zhang Y: Regulation of TET protein stability by calpains. Cell Rep 6(2): 278-284, 2014.
25. Fujii S, Luo RZ, Yuan J, Kadota M, Oshimura M, Dent SR, Kondo Y, Issa JP, Bast RC Jr and Yu Y: Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Hum Mol Genet 12(15): 1791-1800, 2003.
26. Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y and Bast RC Jr: Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112(7): 1489-1502, 2008.
27. Willbanks A, Leary M, Greenshields M, Tyminski C, Heerboth S, Lapinska K, Haskins K and Sarkar S: The evolution of epigenetics: from prokaryotes to humans and its biological consequences. Genet and Epigenet 8: 25-36, 2016.